ClinicalTrials.gg
CompletedNCT04360174Updated Oct 1, 2024Results posted

CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension

A Phase 1 interventional study of OTX-TIC in Ocular Hypertension and Open Angle Glaucoma, sponsored by Ocular Therapeutix, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Primary conditionGlaucoma, Open-AngleRegistry: Ocular HypertensionReclassifiedWhy we changed it
Registry
Ocular Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Ocular Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ocular Therapeutix, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Apr 2018, registered Mar 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Enrollment
246th of 279
19 · median 84
Started
2018
with 15 others
Phase 1
19 of 348
2 open now
Registered
228th of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 246th largest by enrollment of the 279 interventional ones that give a count, is one of 16 that started in 2018, is one of 19 in phase 1, and was the 228th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle glaucoma or ocular hypertension.

Read the detailed description

This is a prospective, multicenter, open label study, to evaluate the safety, tolerability and efficacy of OTX-TIC intracameral implant in subjects with primary open-angle glaucoma or ocular hypertension. The subjects will be followed for approximately 7 months (one-month washout and 6 months follow-up after injected of the OTX-TIC implant).

03

Conditions studied

  • Ocular Hypertension
  • Open Angle Glaucoma

Browse trials for

04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

This study's enrollment of 19 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a documented diagnosis of ocular hypertension or primary open-angle glaucoma
  • Have IOP that is currently controlled as assessed by the Investigator
  • Have open, normal appearing anterior chamber angles as determined by gonioscopy

Exclusion criteria

Exclusion Criteria:

  • Have closed angle glaucoma, narrow angle glaucoma, pseudoexfoliation syndrome, pseudoexfoliation glaucoma, pigment dispersion or pigmentary glaucoma, glaucoma diagnosis prior to 15 years of age, inflammatory, neovascular or other secondary
  • Have a known or suspected allergy and/or to a prostaglandin (i.e. travoprost), fluorescein or to any component of the study products
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    OTX-TIC-Cohort 1

    15 µg (formulation1) implant

    Drug: OTX-TIC

  • Experimental
    OTX-TIC-Cohort 2

    26 µg (formulation1) implant

    Drug: OTX-TIC

  • Experimental
    OTX-TIC-Cohort 3

    15 µg (formulation 2) implant

    Drug: OTX-TIC

  • Experimental
    OTX-TIC-Cohort 4

    5 µg (formulation 3) implant

    Drug: OTX-TIC

Interventions

  • DrugOTX-TIC

    OTX-TIC implant is injection in the anterior chamber of the eye

07

What researchers measure

Primary outcomes

  1. Ocular Treatment Emergent Adverse Events

    All adverse events will be captured throughout the study

    Time frame: Through study completion, 6 months

  2. Efficacy Outcome

    IOP measurements at 8 am

    Time frame: Diurnal IOP [12 Week Visit]

08

Results

Posted Oct 1, 2024

Participant flow

Participant flow — Overall Study
MilestoneOTX-TIC-Cohort 1OTX-TIC-Cohort 2OTX-TIC-Cohort 3OTX-TIC-Cohort 4
Started5455
Completed5455
Not completed0000

Outcome measures

PrimaryOcular Treatment Emergent Adverse Events

All adverse events will be captured throughout the study

Time frame:
Through study completion, 6 months
Reported as:
Number · Number of Treatment-Emergent Events
Ocular Treatment Emergent Adverse Events
Number of Treatment-Emergent EventsOTX-TIC-Cohort 1OTX-TIC-Cohort 2OTX-TIC-Cohort 3OTX-TIC-Cohort 4
Ocular Treatment Emergent Adverse Events9791
PrimaryEfficacy Outcome

IOP measurements at 8 am

Time frame:
Diurnal IOP [12 Week Visit]
Reported as:
Mean · mmHg mean IOP change at wk12 from bln
Efficacy Outcome
mmHg mean IOP change at wk12 from blnOTX-TIC-Cohort 1OTX-TIC-Cohort 2OTX-TIC-Cohort 3OTX-TIC-Cohort 4
Efficacy Outcome-5.6 ± 2.58-7.0 ± 3.27-3.0 ± 14.4-7.4 ± 4.76

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OTX-TIC-Cohort 10/5 (0%)0/5 (0%)3/5 (60%)
OTX-TIC-Cohort 20/4 (0%)0/4 (0%)2/4 (50%)
OTX-TIC-Cohort 30/5 (0%)0/5 (0%)3/5 (60%)
OTX-TIC-Cohort 40/5 (0%)0/5 (0%)1/5 (20%)
Most frequent other events
Most frequent other events
EventOTX-TIC-Cohort 1OTX-TIC-Cohort 2OTX-TIC-Cohort 3OTX-TIC-Cohort 4
Eye DisordersEye disorders3/52/42/51/5
InvestigationsEye disorders0/50/43/50/5
Uncoded TermsEye disorders0/50/42/50/5
Congenital, familial and genetic disordersEye disorders1/50/40/50/5

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)OTX-TIC-Cohort 1OTX-TIC-Cohort 2OTX-TIC-Cohort 3OTX-TIC-Cohort 4Total
<=18 years00000
Between 18 and 65 years01225
>=65 years533314
Sex: Female, Male
Sex: Female, Male(Participants)OTX-TIC-Cohort 1OTX-TIC-Cohort 2OTX-TIC-Cohort 3OTX-TIC-Cohort 4Total
Female344415
Male20114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OTX-TIC-Cohort 1OTX-TIC-Cohort 2OTX-TIC-Cohort 3OTX-TIC-Cohort 4Total
Hispanic or Latino01146
Not Hispanic or Latino534113
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OTX-TIC-Cohort 1OTX-TIC-Cohort 2OTX-TIC-Cohort 3OTX-TIC-Cohort 4Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American02305
White522514
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)OTX-TIC-Cohort 1OTX-TIC-Cohort 2OTX-TIC-Cohort 3OTX-TIC-Cohort 4Total
United States545519
09

Study locations

5 sites
  • Ocular Therapeutix, Inc.
    Petaluma, California 94954, United States
  • Ocular Therapeutix, Inc.
    Torrance, California 90505, United States
  • Ocular Therapeutix, Inc
    Roswell, Georgia 30076, United States
  • Ocular Therapeutix, Inc.
    Austin, Texas 78731, United States
  • Ocular Therapeutix, Inc.
    Racine, Wisconsin 53405, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in May 2021, 36 months.

Results were first posted in Oct 2024, 3 years 4 months after primary completion.

Of 17 phase 1 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2020
First posted
Apr 24, 2020
StartActual
Apr 25, 2018
Primary completionActual
May 24, 2021
CompletionActual
May 24, 2021
Results first posted
Oct 1, 2024
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04360174
Responsible party
Sponsor
First posted
Apr 24, 2020
Start date
Apr 25, 2018
Primary completion
May 24, 2021
Completion
May 24, 2021
Results posted
Oct 1, 2024
Last update
Oct 1, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion